
BVS
Bioventus Inc
- Overview
- Forecast
- Valuation
- Earnings

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
7.030
Open
6.920
VWAP
6.88
Vol
381.78K
Mkt Cap
572.14M
Low
6.760
Amount
2.63M
EV/EBITDA(TTM)
9.78
Total Shares
63.83M
EV
930.57M
EV/OCF(TTM)
25.67
P/S(TTM)
0.81
Bioventus Inc. is a medical device company. The Company’s portfolio of products is grouped into three areas. Its Pain Treatments include the Knee Osteoarthritis (KOA) area, and Peripheral Nerve Stimulation (PNS) area. Its Surgical Solutions include Ultrasonics, which offers precision bone resection for patients with degenerative spine conditions and spinal deformities, and Bone Graft Substitutes (BGS), which includes a range of products that facilitate optimal bone fusion following a surgical procedure. Its Restorative Therapies comprise Fracture Care that provide low-intensity pulse ultrasound to help patients who suffer from bone fractures that do not heal through traditional methods. It offers a diverse portfolio of products to support physicians in relieving pain and addressing musculoskeletal challenges across indications and clinical areas, including knee, hand and upper extremities, foot and ankle, podiatry, trauma, general surgery, spine and neurosurgery.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q3
FY2025Q4
FY2026Q1
137.64M
-0.95%
0.116
+93.87%
156.06M
+1.57%
0.221
+47.32%
132.50M
+6.96%
0.130
+62.5%
Estimates Revision
The market is revising No Change the revenue expectations for Bioventus Inc. (BVS) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 2.82%.
Revenue Estimates for FY2025
No Change

0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change

0.00%
In Past 3 Month
Stock Price
Go Up

+2.82%
In Past 3 Month
4 Analyst Rating

63.49% Upside
Wall Street analysts forecast BVS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BVS is 11.33 USD with a low forecast of 7.00 USD and a high forecast of 15.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
1 Hold
0 Sell
Strong Buy

63.49% Upside
Current: 6.930

Low
7.00
Averages
11.33
High
15.00

63.49% Upside
Current: 6.930

Low
7.00
Averages
11.33
High
15.00
Cantor Fitzgerald
Ross Osborn
Overweight
initiated
$12
2025-07-07
Reason
Cantor Fitzgerald
Ross Osborn
Price Target
$12
2025-07-07
initiated
Overweight
Reason
Cantor Fitzgerald analyst Ross Osborn initiated coverage of Bioventus with an Overweight rating and $12 price target.
Canaccord Genuity
Caitlin Cronin
Strong Buy
Maintains
$15
2025-03-17
Reason
Canaccord Genuity
Caitlin Cronin
Price Target
$15
2025-03-17
Maintains
Strong Buy
Reason
JP Morgan
Robbie Marcus
Sell
to
Hold
Upgrades
$12 → $13
2024-12-17
Reason
JP Morgan
Robbie Marcus
Price Target
$12 → $13
2024-12-17
Upgrades
Sell
to
Hold
Reason
JPMorgan upgraded Bioventus to Neutral from Underweight with a price target of $13, up from $12. The firm cites better visibility into the company's growth and several quarters of improved execution for the upgrade. 2024 marked a return to stability for Bioventus, with hyaluronic acid headwinds now lapped and "fully in the rearview and pockets of strength in areas like Ultrasonics," the analyst tells investors in a research note. As such, JPMorgan feels incrementally more positive about Bioventus into 2025.
Canaccord Genuity
William Plovanic
Strong Buy
Maintains
$12 → $15
2024-11-06
Reason
Canaccord Genuity
William Plovanic
Price Target
$12 → $15
2024-11-06
Maintains
Strong Buy
Reason
Canaccord analyst William Plovanic raised the firm's price target on Bioventus to $15 from $12 and keeps a Buy rating on the shares. The firm said they posted a strong Q3, beating revenue, adj. EBITDA, and pro forma EPS expectations. It saw double-digit growth in both its Pain Treatments and Surgical Solutions businesses while continuing improved sales force execution in its Exogen business.
Craig-Hallum
Alexander Nowak
Strong Buy
Maintains
$12 → $17
2024-09-27
Reason
Craig-Hallum
Alexander Nowak
Price Target
$12 → $17
2024-09-27
Maintains
Strong Buy
Reason
Craig-Hallum raised the firm's price target on Bioventus to $17 from $12 and keeps a Buy rating on the shares following recent checks and positive impressions from recent investor meetings. There are strong tailwinds across the company's portfolio, and Craig-Hallum sees upside to Street estimates as a result, the analyst tells investors in a research note. Craig-Hallum believes the company remains on track to divest the Advanced Rehab business.
Canaccord Genuity
William Plovanic
Strong Buy
Maintains
$8 → $12
2024-08-13
Reason
Canaccord Genuity
William Plovanic
Price Target
$8 → $12
2024-08-13
Maintains
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Bioventus Inc (BVS.O) is 9.85, compared to its 5-year average forward P/E of 23.51. For a more detailed relative valuation and DCF analysis to assess Bioventus Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
23.51
Current PE
9.85
Overvalued PE
56.44
Undervalued PE
-9.43
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Undervalued
5Y Average EV/EBITDA
9.03
Current EV/EBITDA
6.90
Overvalued EV/EBITDA
11.05
Undervalued EV/EBITDA
7.01
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair
5Y Average PS
0.91
Current PS
0.79
Overvalued PS
1.36
Undervalued PS
0.45
Financials
Annual
Quarterly
FY2025Q2
YoY :
-2.35%
147.66M
Total Revenue
FY2025Q2
YoY :
+16.06%
18.62M
Operating Profit
FY2025Q2
YoY :
-127.10%
9.27M
Net Income after Tax
FY2025Q2
YoY :
-127.50%
0.11
EPS - Diluted
FY2025Q2
YoY :
+67.42%
25.26M
Free Cash Flow
FY2025Q2
YoY :
+1.47%
68.16
Gross Profit Margin - %
FY2025Q2
YoY :
+284.71%
6.04
FCF Margin - %
FY2025Q2
YoY :
-127.75%
6.28
Net Margin - %
FY2025Q2
N/A
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
150.5K
USD
6
6-9
Months
589.8K
USD
7
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
150.5K
USD
6
6-9
Months
589.8K
USD
7
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
BVS News & Events
Events Timeline
2025-08-06 (ET)
2025-08-06
07:13:32
Bioventus sees FY25 EPS 64c-68c, consensus 66c

2025-08-06
07:12:53
Bioventus reports Q2 EPS 21c, consensus 20c

2025-08-04 (ET)
2025-08-04
08:14:24
Bioventus enters $400M senior secured credit agreement

Sign Up For More Events
Sign Up For More Events
News
9.0
07-30NewsfilterBioventus Receives FDA 510(k) Clearances for two Next-Generation Peripheral Nerve Stimulation Products
4.0
07-07BenzingaCantor Fitzgerald Initiates Coverage On Bioventus with Overweight Rating, Announces Price Target of $12
6.5
06-20NASDAQ.COMPeek Under The Hood: FHLC Has 21% Upside
Sign Up For More News
People Also Watch

ADV
Advantage Solutions Inc
1.885
USD
+2.45%

CEVA
CEVA Inc
21.330
USD
-1.80%

SITC
Site Centers Corp
11.350
USD
+1.16%

SCVL
Shoe Carnival Inc
19.930
USD
+1.84%

TSAT
Telesat Corp
21.000
USD
-0.05%

GCT
GigaCloud Technology Inc
30.230
USD
+4.57%

VTS
Vitesse Energy Inc
24.850
USD
0.00%

GLDD
Great Lakes Dredge & Dock Corp
11.470
USD
-0.95%

IE
Ivanhoe Electric Inc
9.820
USD
-3.16%

YEXT
Yext Inc
7.730
USD
-1.40%
FAQ

What is Bioventus Inc (BVS) stock price today?
The current price of BVS is 6.93 USD — it has increased 0.14 % in the last trading day.

What is Bioventus Inc (BVS)'s business?

What is the price predicton of BVS Stock?

What is Bioventus Inc (BVS)'s revenue for the last quarter?

What is Bioventus Inc (BVS)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Bioventus Inc (BVS)'s fundamentals?

How many employees does Bioventus Inc (BVS). have?
